“Omics” have accelerated drug discovery for clinical practice and are therefore promising elements in optimising IBD treatment . They can be used for each of the four basic components in IBD pathogenesis (see Table).
Table: Basic components of IBD and their treatment strategies 
Omics-based biomarkers for clinical practice are able to detect subtypes (molecular signatures). Thus, they suit a holistic view of the patient integrating the person, the affected organ, its lesion, as well as cell and molecular structures [23,34].
- Kralyevic S, et al. EMBO Rep. 2004;5:837-42.
- Stylianou DE. Mol Diagn Ther. 2018;22:11-23.
- Fiocchi C, et al. ECCO 20...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Higher rates of remission and healing with vedolizumab vs. TNF antagonist Next Article
Significantly increased risk of CRC and/or HGD after appendectomy in UC »